New combo therapy aims to tame rare blood vessel disease
NCT ID NCT00647166
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested whether adding azathioprine to standard corticosteroid treatment helps people with certain types of vasculitis (blood vessel inflammation) achieve remission and avoid relapses. 114 newly diagnosed patients without poor prognosis factors took part. The goal was to see if the combination therapy reduces treatment failure or relapse within two years compared to steroids alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- corticosteroid and azathioprine
- What this could lead to
- If successful, this could offer a more effective treatment plan for people with certain types of vasculitis, lowering the chance of the disease coming back.
- What could go wrong
- This is a completed phase 3 trial, but the results may not apply to all patients. Adding azathioprine could increase side effects without guaranteeing better outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AT DIAGNOSIS OR WITHIN THE FIRST 15 DAYS FOLLOWING INITIATION OF CORTICOSTEROIDS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hopital Cochin Pôle de Médecine UF Médecine Interne
Paris, 75014, France